Last reviewed · How we verify
oxaliplatin+Leucovorin+5-FU
Oxaliplatin works by interfering with DNA replication in cancer cells, while 5-FU is a thymidylate synthase inhibitor that disrupts DNA synthesis, and Leucovorin is a folate analog that helps stabilize 5-FU.
Oxaliplatin works by interfering with DNA replication in cancer cells, while 5-FU is a thymidylate synthase inhibitor that disrupts DNA synthesis, and Leucovorin is a folate analog that helps stabilize 5-FU. Used for Adjuvant treatment of colon cancer, First-line treatment of metastatic colorectal cancer.
At a glance
| Generic name | oxaliplatin+Leucovorin+5-FU |
|---|---|
| Also known as | Leucovorin (LV) |
| Sponsor | Xu jianmin |
| Drug class | Platinum-based chemotherapy |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Oxaliplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, which interfere with DNA replication and transcription. 5-FU is a pyrimidine analog that inhibits thymidylate synthase, leading to a decrease in DNA synthesis. Leucovorin, also known as folinic acid, is a reduced folate that helps stabilize 5-FU and increase its effectiveness.
Approved indications
- Adjuvant treatment of colon cancer
- First-line treatment of metastatic colorectal cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea and vomiting
- Fatigue
- Neuropathy
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (PHASE2)
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (PHASE2)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxaliplatin+Leucovorin+5-FU CI brief — competitive landscape report
- oxaliplatin+Leucovorin+5-FU updates RSS · CI watch RSS
- Xu jianmin portfolio CI